Latest News Archive

Please select Category, Year, and then Month to display items

Prof Allan Boesak on the role of the church

02 January 2025 | Story Edzani Nephalela | Photo Lethabo Machabaphala

In a world increasingly defined by the stark contrasts of power and vulnerability, the concept of democracy often reveals itself as a double-edged sword. For the children of struggle – those who have grown up amid the chaos of inequality and conflict – democracy can feel like a distant promise, an ideal often outmanned by the realities they face. The deception of hope lingers in the air as aspirations clash with systemic barriers, leaving many to navigate a landscape where a harsh daily existence obscures the principles of freedom and justice. This exploration seeks to uncover the intricate dynamics between hope and disillusionment, shedding light on the lived experiences of those who yearn for a brighter future yet grapple with the weight of unfulfilled promises.

This was the essence of the public lecture titled Outmanned by Democracy: Children of Struggle, Deception, and Hope, presented by Prof Allan Boesak, a theologian and political activist, on the Bloemfontein Campus.

Prof Boesak confronted the continuous socio-economic challenges faced by South Africa and other nations, including racism, narrow ethnic nationalism, and the revival of tribalism. He emphasised the role of churches in tackling these issues. “The responsibility of churches is to articulate what politicians are often afraid to say,” he stated. “Put your ideologies into practice and leverage your power as ministers of the Word to shape the future and reclaim the dignity of your people. This is where unity transcends colour and stature. Consider the various roles that churches could play in reconciling communities, as seen in the Gaza crisis.”

During his visit to the UFS Faculty of Theology and Religion, Prof Boesak also launched a four-volume set titled The Fire, The River and the Scorched Earth: Fifty Years of Black Theology Through the Lens of Allan Boesak. The first three volumes include his lectures and responses from various theologians, while the fourth contains his sermons. This body of work aims to document, critique, and celebrate the contributions of black theology, highlighting its role in the struggle for justice and liberation and underscoring Prof Boesak’s unwavering commitment to freedom, liberation, and democracy.

In a time when hope and disillusionment coexist, Prof Boesak’s insights remind us of the transformative power of faith and activism in the continuing fight for a more equitable world

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept